The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwHRMM 2025 | Understanding the biology of t(4;14) myeloma: genomics, transcriptomics, and epigenomics
Mattia D’Agostino, MD, University of Turin, Turin, Italy, discusses the role of genomics, transcriptomics, and epigenomics in understanding the biology of high-risk multiple myeloma, particularly with translocation t(4;14). He highlights that these techniques have helped to identify genomic drivers, pathways, and the impact of NSD2 disruption. This interview took place at the 2nd International Workshop on High-Risk Multiple Myeloma (iwHRMM 2025), held in Charleston, SC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Genomics and transcriptomics can help to dissect this group of patients. First of all, genomics is the only technique with which you can really look at the NSD2 disruption site. The transcriptomics really helped us to understand what are the genomic drivers and the pathways involved in this kind of patients. And let me add that even more important has been the epigenomics because this group of patients have a hypermethylated genome due to the NSD2 function overexpression...
Genomics and transcriptomics can help to dissect this group of patients. First of all, genomics is the only technique with which you can really look at the NSD2 disruption site. The transcriptomics really helped us to understand what are the genomic drivers and the pathways involved in this kind of patients. And let me add that even more important has been the epigenomics because this group of patients have a hypermethylated genome due to the NSD2 function overexpression. So I think that these three techniques really helped us to move forward in understanding the biology of these patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
